Skip to main content
Premium Trial:

Request an Annual Quote

CHDI Extends Evotec Huntington's Collaboration Through 2017

NEW YORK (GenomeWeb News) – Evotec said today that the CHDI Foundation has extended and expanded the two parties' collaboration on Huntington's disease research through 2017.

Under the terms of the agreement, CHDI will fund up to 52 full-time scientists at Evotec over the next three years. The collaboration, which began in 2006, aims to use Evotec's high-throughput screening and proteomics platforms for Huntington's drug discovery.

In addition to proteomics services, Evotec also provides CHDI research capabilities including integrated biology and chemistry supported by compound and library management, target validation, stem cell research, high-content screening, computational chemistry, in vitro pharmacokinetics, and protein production.

"Evotec represents one of our largest and longest standing relationships and continues to be an important strategic partner in our search for effective treatments for Huntington's disease," Robert Pacifici, chief scientific officer at CHDI, said in a statement. "Their integrated drug discovery capabilities are helping us to discover novel targets and to advance drug candidates towards the clinic and we look forward to continuing to work with Evotec over the coming years."

Financial and other terms of the agreement were not disclosed.